Sale!

Lung Cancer Panel 7 EGFRBRAFALK1ROS1 MET Test

Original price was: 9,600 د.إ.Current price is: 7,200 د.إ.

-25%

The “Lung Cancer Panel 7 EGFRBRAFALK1ROS1 MET Test” is a comprehensive genomic test offered by DNA Labs UAE, designed to identify genetic mutations in lung cancer patients. This panel specifically targets mutations in seven critical genes: EGFR, BRAF, ALK, ROS1, and MET, which are known to influence the growth and spread of lung cancer cells. By detecting these mutations, the test provides essential information that can guide personalized treatment plans, including targeted therapies that may offer better outcomes for patients.

The cost of the test is 7200 AED. Conducted in the advanced facilities of DNA Labs UAE, this test represents a significant step forward in the precision medicine approach to treating lung cancer, allowing for more tailored and effective treatment strategies based on the genetic profile of an individual’s cancer.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Lung Cancer Panel 7 EGFRBRAFALK1ROS1 MET Test – DNA Labs UAE

Are you in need of a Lung Cancer Panel 7 EGFRBRAFALK1ROS1 MET Test in UAE? Look no further! DNA Labs UAE offers this comprehensive diagnostic test at a cost of AED 7200.0.

Test Details

The Lung Cancer Panel 7 is a diagnostic test that analyzes the DNA of lung cancer cells to identify mutations in specific genes that are associated with the development and progression of the disease. This panel includes analysis of the following seven genes:

  1. EGFR (epidermal growth factor receptor) – mutations in this gene are commonly found in non-small cell lung cancer and can be targeted with specific drugs.
  2. BRAF (B-Raf proto-oncogene, serine/threonine kinase) – mutations in this gene are rare in lung cancer but may indicate a poorer prognosis.
  3. ALK1 (anaplastic lymphoma kinase) – rearrangements of this gene are found in a small subset of lung cancers and can be targeted with specific drugs.
  4. ROS1 (c-ros oncogene 1) – rearrangements of this gene are also found in a small subset of lung cancers and can be targeted with specific drugs.
  5. MET (hepatocyte growth factor receptor) – overexpression of this gene has been linked to resistance to certain cancer treatments.
  6. RET (rearranged during transfection) – rearrangements of this gene are found in a small subset of lung cancers and can be targeted with specific drugs.
  7. KRAS (Kirsten rat sarcoma viral oncogene homolog) – mutations in this gene are commonly found in non-small cell lung cancer and are associated with a poorer prognosis.

The Lung Cancer Panel 7 test can help guide treatment decisions by identifying specific genetic mutations that may respond to targeted therapies. It may also provide information about the prognosis of the disease and help identify patients who may benefit from clinical trials of new treatments.

Test Components

The Lung Cancer Panel 7 EGFRBRAFALK1ROS1 MET Test requires paraffin embedded tissue blocks as the sample condition.

Price and Report Delivery

The cost of the Lung Cancer Panel 7 EGFRBRAFALK1ROS1 MET Test is AED 7200.0. The report will be delivered within 5-7 days.

Method and Test Type

The Lung Cancer Panel 7 EGFRBRAFALK1ROS1 MET Test utilizes FISH (Fluorescence In Situ Hybridization) and Sanger Sequencing methods. It falls under the category of Genetics tests.

Referring Doctor and Test Department

This test is conducted under the supervision of an Oncology specialist. It is performed in the Test Department of DNA Labs UAE.

Pre Test Information

Please note that the Lung Cancer Panel 7 EGFRBRAFALK1ROS1 MET Test requires a Doctor’s prescription. However, it is not applicable for surgery and pregnancy cases or individuals planning to travel abroad.

Make an informed decision about your lung cancer diagnosis and treatment by opting for the Lung Cancer Panel 7 EGFRBRAFALK1ROS1 MET Test at DNA Labs UAE. Contact us today!

Test Name Lung Cancer Panel 7 EGFRBRAFALK1ROS1 MET Test
Components Paraffin embedded tissue blocks
Price 7200.0 AED
Sample Condition Tumor tissue
Report Delivery 5-7 days
Method FISH,Sanger Sequencing
Test type Genetics
Doctor Oncology
Test Department:
Pre Test Information Lung Cancer Panel 7 (EGFR,BRAF,ALK1,ROS1, MET) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

The Lung Cancer Panel 7 is a diagnostic test that analyzes the DNA of lung cancer cells to identify mutations in specific genes that are associated with the development and progression of the disease. The panel includes analysis of seven genes:

1. EGFR (epidermal growth factor receptor) – mutations in this gene are commonly found in non-small cell lung cancer and can be targeted with specific drugs.

2. BRAF (B-Raf proto-oncogene, serine/threonine kinase) – mutations in this gene are rare in lung cancer but may indicate a poorer prognosis.

3. ALK1 (anaplastic lymphoma kinase) – rearrangements of this gene are found in a small subset of lung cancers and can be targeted with specific drugs.

4. ROS1 (c-ros oncogene 1) – rearrangements of this gene are also found in a small subset of lung cancers and can be targeted with specific drugs.

5. MET (hepatocyte growth factor receptor) – overexpression of this gene has been linked to resistance to certain cancer treatments.

6. RET (rearranged during transfection) – rearrangements of this gene are found in a small subset of lung cancers and can be targeted with specific drugs.

7. KRAS (Kirsten rat sarcoma viral oncogene homolog) – mutations in this gene are commonly found in non-small cell lung cancer and are associated with a poorer prognosis.

The Lung Cancer Panel 7 test can help guide treatment decisions by identifying specific genetic mutations that may respond to targeted therapies. It may also provide information about the prognosis of the disease and help identify patients who may benefit from clinical trials of new treatments.